EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on intracranial atherosclerotic plaque characteristics and low density lipoprotein-cholesterol (LDL-C) reduction: a real-world observational study

Zhenzhen Li, Xiaohui Li, Yiting Zhang, Jingwen Qi, Lifan Ji, Shuo Li, Mengmeng Gu, Yukai Liu, Yuqiao Zhang, Yanping Mei, Meng Wang, Junshan Zhou und 3 weitere

PeerJ · 2026

DOI: 10.7717/peerj.20668 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PeerJ, 2026. Verfasst von Zhenzhen Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Plaque, Atherosclerotic, PCSK9 Inhibitors, Cholesterol, LDL, Atorvastatin. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Innovation 2030–Major Program of Brain Science and Brain-Inspired Intelligence Research, National Natural Science Foundation of China, Nanjing Medical Science and Technology Development Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose The combination of PCSK9 inhibitors and moderate statin therapy effectively stabilizes intracranial atherosclerotic plaques in patients with intracranial atherosclerotic stenosis (ICAS). This study aimed to explore the effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on plaque characteristics in patients with symptomatic ICAS (sICAS) in the anterior circulation over a 6-month follow-up.

Methods

This study is a single-center, prospective, observational study, which continuously included stroke patients with sICAS in the anterior circulation. The patients were divided into two groups: the standard treatment group (atorvastatin) or the intensive treatment group (evolocumab combined with atorvastatin). The primary outcome is the change of atherosclerotic plaque characteristics over 6 months.

Results

A total of 50 patients were enrolled in this study, with 34 patients ultimately included in the analysis (15 in the standard treatment group and 19 in the intensive treatment group). Both groups succeeded in reducing low-density lipoprotein-cholesterol (LDL-C) levels, and the intensive treatment group showed a more pronounced reduction ( P < 0.001). The intensive treatment group exhibited a significant improvement in the degree of stenosis ( P = 0.001). Notable disparities were observed between the standard treatment group and the intensive treatment group regarding percentage change of plaque length (−85.70 vs. −1.25%, P = 0.009) and plaque volume after 6 months (265.06 vs . 125.34 mm 3 , P = 0.018).

Conclusion

Compared with statins alone, the utilization of PCSK9 inhibitors demonstrated a marked improvement in the progression of arteriosclerosis, effectively reducing stenosis degree, plaque length, and volume.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plaque, AtheroscleroticPCSK9 InhibitorsCholesterol, LDLAtorvastatinIntracranial ArteriosclerosisAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsHumansMaleFemaleProspective StudiesMiddle AgedAgedDrug Therapy, CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsTreatment OutcomeProprotein Convertase 9

Stichwörter der Autor:innen

High-resolution magnetic resonance imagingLow density lipoprotein-cholesterolPCSK9 inhibitorsPlaque characteristicsSymptomatic intracranial atherosclerotic stenosis

Substanzen

PCSK9 InhibitorsCholesterol, LDLAtorvastatinevolocumabPCSK9 protein, humanAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9

Autor:innen und Institutionen

  • Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
  • School of Basic Medicine and Clinical Pharmacy, Nanjing First Hospital, China Pharmaceutical University, Nanjing, China.
  • Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
  • Department of Neurology, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, China.

Förderung

  • National Science and Technology Innovation 2030–Major Program of Brain Science and Brain-Inspired Intelligence Research
  • National Natural Science Foundation of China
  • Nanjing Medical Science and Technology Development Foundation
  • Nanjing Medical University Science and Technique Development
  • Medjaden Academy & Research Foundation for Young Scientists
  • Nanjing Medical University Science and Technique Development Foundation Project
  • Nanjing Medical Science and Technique Development Foundation Project
  • Postgraduate Research & Practice Innovation Program of Jiangsu Province

Zitieren

APA

Li, Z., Li, X., Zhang, Y., Qi, J., Ji, L., Li, S., Gu, M., Liu, Y., Zhang, Y., Mei, Y., Wang, M., Zhou, J., Su, M., Zhu, L., & Deng, Q. (2026). Impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on intracranial atherosclerotic plaque characteristics and low density lipoprotein-cholesterol (LDL-C) reduction: a real-world observational study. PeerJ. https://doi.org/10.7717/peerj.20668

Vancouver

Li Z, Li X, Zhang Y, Qi J, Ji L, Li S, et al. Impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on intracranial atherosclerotic plaque characteristics and low density lipoprotein-cholesterol (LDL-C) reduction: a real-world observational study. PeerJ. 2026. doi:10.7717/peerj.20668

BibTeX
@article{Li2026,
  author = {Li, Zhenzhen and Li, Xiaohui and Zhang, Yiting and Qi, Jingwen and Ji, Lifan and Li, Shuo and Gu, Mengmeng and Liu, Yukai and Zhang, Yuqiao and Mei, Yanping and Wang, Meng and Zhou, Junshan and Su, Mouxiao and Zhu, Lin and Deng, Qiwen},
  title = {Impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on intracranial atherosclerotic plaque characteristics and low density lipoprotein-cholesterol (LDL-C) reduction: a real-world observational study},
  journal = {PeerJ},
  year = {2026},
  doi = {10.7717/peerj.20668}
}
Kostenlos starten →